Rocket Pharmaceuticals, Inc. Adjustment of Warrants Granted for Services
Rocket Pharmaceuticals, Inc. (RCKT) reported Adjustment of Warrants Granted for Services of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:AdjustmentOfWarrantsGrantedForServices · last filed 2024-02-27
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for the quarter ending 2022-06-30 was $0.00.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for the quarter ending 2022-03-31 was $0.00.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for fiscal 2023 was $0.00.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for fiscal 2021 was $12.78M, a 51.88% decline from fiscal 2020.
- Rocket Pharmaceuticals, Inc. adjustment of warrants granted for services for fiscal 2020 was $26.56M.
| Period end | Adjustment of Warrants Granted for Services 3 month | Adjustment of Warrants Granted for Services 6 month | Adjustment of Warrants Granted for Services 9 month | Adjustment of Warrants Granted for Services 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | $5.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $5.20M derived: sum of 3 quarters · filed 2024-02-27 | $12.78M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $5.20M derived: sum of 2 quarters · filed 2024-02-27 | $12.78M derived: sum of 3 quarters · filed 2024-02-27 | $12.78M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $12.78M derived: sum of 2 quarters · filed 2024-02-27 | $12.78M derived: sum of 3 quarters · filed 2024-02-27 | $12.78M 10-K · filed 2024-02-27 |
| 2021-09-30 | $7.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $7.58M derived: sum of 2 quarters · filed 2022-11-04 | $7.58M 10-Q · filed 2022-11-04 | $34.14M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $26.56M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | $26.56M derived: sum of 2 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $26.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $26.56M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |